SCHEDULE: Boxer Capital Discloses 6.67% Stake in Surrozen

Boxer Capital Management and associated entities have filed a Schedule 13G reporting a 6.67% beneficial ownership stake in Surrozen, Inc.

Summary

• Boxer Capital Management, LLC, along with Boxer Holdings, LP, Boxer Holdings GP, LLC, and Aaron Davis, reported a collective beneficial ownership of 766,318 shares of Surrozen, Inc. common stock.
• This holding represents 6.67% of the company's total outstanding common stock.
• The ownership percentage is based on 11,486,707 shares outstanding as of March 19, 2026.
• The reporting persons certify that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure indicating institutional interest without signaling a change in corporate strategy or control.

Positives

• Institutional investment interest from Boxer Capital suggests confidence in the company's long-term prospects.
• The filing confirms a significant stake (6.67%) held by a professional investment management firm.

Negatives

• None identified in this regulatory disclosure.

Risks

• The investment is subject to general market risks associated with the biotechnology sector.
• The reporting persons have disclaimed any intent to influence or change control, which may limit their role in corporate governance.

Future Outlook

The filing does not provide forward-looking guidance regarding the company's operations, as it is a standard disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory requirements for institutional investors crossing the 5% ownership threshold. This activity is common in the biotech sector where venture and institutional capital often maintain significant positions in emerging drug development companies.

Comparison to Industry Standards

• The filing adheres to standard SEC requirements for passive institutional investors.
• The 6.67% stake is consistent with typical minority interest positions held by specialized healthcare investment firms.

Stakeholder Impact

• Shareholders may view the entry or maintenance of an institutional position as a sign of market validation.

Next Steps

• The reporting persons will continue to monitor their investment in the ordinary course of business.

Key Dates

Keywords

Surrozen, Boxer Capital, Schedule 13G, Biotechnology, Institutional Ownership, Common Stock